Clinical Trials Logo

Clinical Trial Summary

Despite recent therapeutic advancements, the outcome of young adults with Philadelphia-negative (Ph-neg) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) remains unsatisfactory, especially in those patients with high-risk disease features. In young adults pediatric-based chemotherapy approaches improve outcome. Furthermore, there is evidence that pre-transplant antibody-based therapy may render patients with positive minimal residual disease (MRD+) to an MRD-negative status (MRD-) and that this may be associated with improved post-transplant outcome. This is prospective study to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be performed.


Clinical Trial Description

This is a national, multicenter, phase II clinical trial to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be assessed. Young-adult patients eligible with Ph-neg ALL, LBL and mixed phenotype acute leukemia (MPAL) will undergo risk stratification and started on the pediatric Italian Association of Pediatric Hematology Oncology-Berlin-Frankfurt-Münster (AIEOP-BFM) 2009 protocol. Patients defined as having non-high-risk disease features (non-HR) as defined by MRD and/or cytogenetic criteria will complete the non-HR chemotherapy arm per protocol. Patients designated as having HR disease features after 2 induction blocks will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation. All patients will be centrally assessed for MRD and for Ph-like status. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04334993
Study type Interventional
Source Israeli Medical Association
Contact Ofir Wolach, MD
Phone +972-3-9378116
Email ofirw@clalit.org.il
Status Recruiting
Phase Phase 2
Start date January 1, 2021
Completion date May 1, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06041490 - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation Phase 2
Recruiting NCT03978663 - Three Fraction Radiation to Induce Immuno-Oncologic Response N/A
Withdrawn NCT05120622 - Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT05254899 - Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL Phase 2
Recruiting NCT04947098 - Prevent Cancer- Greenville
Recruiting NCT06020443 - Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France. N/A
Completed NCT02308280 - Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients Phase 2
Active, not recruiting NCT06046625 - Needs and Preferences of Patients With Head-neck Cutaneous SCC
Recruiting NCT06277050 - Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma Phase 3
Completed NCT03343249 - Adjunctive Smart Phone Based Smoking Cessation Treatment N/A
Recruiting NCT06327568 - Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens
Terminated NCT01941550 - Neoadjuvant Chemotherapy With Cabazitaxel Phase 2
Recruiting NCT05482880 - Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Recruiting NCT05498272 - Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations Phase 2
Terminated NCT01479192 - Fenretinide in Healthy Young Women at Genetic and Familial Risk Phase 3
Recruiting NCT05557487 - Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
Recruiting NCT04217356 - Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
Recruiting NCT04740866 - Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer N/A
Recruiting NCT04905329 - A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
Active, not recruiting NCT01827137 - WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation N/A